[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spondyloarthritis-spa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spondyloarthritis-spa":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,66,99,132,161,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100571308","pain-in-inflammatory-joint-diseases-100571308",false,"NCT06718569","Pain in Inflammatory Joint Diseases","Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management","Nor-Pain","Inclusion Criteria:\n\n* All patients who initiate or switch biological or targeted synthetic DMARDs\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":20,"type":21},350,"ESTIMATED","OBSERVATIONAL","Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.",[25,26,27,28,29,30],"Arthritis","Arthritis, Juvenile Idiopathic","Arthritis,Rheumatoid","Arthritis, Reactive","Arthritis, Psoriatic","Spondyloarthritis (SpA)","RECRUITING","2026-04-07",{"date":34,"type":35},"2026-04-13","ACTUAL",{"date":37,"type":35},"2025-11-11",{"date":39,"type":21},"2027-11",{"name":41,"class":42},"Diakonhjemmet Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100610649","whole-body-mri-for-non-invasive-lesion-detection-and-therapy-follow-up-study-with-patients-with-radiographic-axspa-and-non-radiographic-axspa-100610649","NCT07230327","Whole Body MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Radiographic axSpA and Non-radiographic axSpA","Research on a New Disease Activity Assessment System for axSpA Based on Whole-body Magnetic Resonance Imaging Cohort","NJSpAM","Inclusion Criteria:\n\nInclude newly referred patients if:\n\nThe onset of symptoms (back pain\u002Farthritis\u002Fenthesitis) \\\u003C 45 years\n\nUndiagnosed disease with the following symptoms:\n\nchronic back pain (duration of back pain more than 3 months) and\u002For peripheral arthritis (asymmetric arthritis\u002Fpredominantly of the lower limbs) and\u002For enthesitis and\u002For dactylitis\n\nExclusion Criteria:\n\nAnd diagnosed with non-radiographic or radiographic axial SpA",{"count":53,"type":21},100,"This study aims to further improve and expand the WB-MRI imaging evaluation cohort of axSpA patients to complete dynamic follow-up and condition assessment. Based on the WB-MRI features, the association of WB-MRI signs with disease activity, inflammation, and structural damage will be analyzed. At the same time, in-depth data mining was conducted and machine learning was used to construct a new axSpA disease activity assessment model based on WB-MRI data, and the accuracy and reliability of the model were clearly evaluated in the discovery cohort and validation cohort.",[30,56],"Whole-body MRI (WBMRI)","2025-11-14",{"date":59,"type":35},"2025-11-17",{"date":61,"type":35},"2022-01-01",{"date":63,"type":21},"2026-12",{"name":65,"class":42},"The First Affiliated Hospital with Nanjing Medical University",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100567304","comfi---a-combined-fatigue-intervention-100567304","NCT06666452","COMFI - a COMbined Fatigue Intervention","The Feasibility Test of a COMbined Fatigue Intervention (COMFI) for People With Inflammatory Athritis","COMFI","Inclusion Criteria:\n\n1. Current fatigue level (VAS-Fatigue: The VAS-fatigue has to be 60 or above.\n2. Must have experienced fatigue as a challenge for at least the last 3 months\n3. A rheumatologist-confirmed diagnosis of Rheumatoid Arthritis, Psoriatic Arthritis, or Spondyloarthritis\n4. The patient is in a stable phase regarding disease activity. This means no current plans to adjust pharmacological treatment, and no changes in treatment in the last 3 months (DMARDs or steroids) incl. steroid injections.\n5. Must be affiliated with the Danish Hospital of Rheumatic Diseases or Skaane University Hospital in Lund.\n6. Age ≥18 years.\n7. Must be able to speak and write Danish or Swedish well enough to participate in group discussions without an interpreter.\n8. The participant must be interested in actively participating and making changes to daily life to improve their condition.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. Critical\u002Fserious illness:\n\n   * Diseases with an expected survival of \\\u003C 2 years (e.g., cancer)\n   * Heart failure with NYHA class 3 or 4\n   * Kidney failure with eGFR \\\u003C 30\n   * Severe anemia - hemoglobin ≤ 5.0 mmol\u002FL\n3. Clarification of known diseases, which must be well-treated or in remission:\n\n   * Diabetes: HbA1c \\>53 mmol\u002Fmol is excluded if dysregulated\n   * Thyroid disease: TSH: 0.4-4.0 mE\u002FL. Excluded if dysregulated\n4. A medical condition that would make the proposed interventions unsuitable\u002Fimpossible for group participation or hinder the ability to give informed consent:\n\n   * Unstable psychiatric illness\n   * Dementia or other severe cognitive problems\n   * Hearing loss\u002Fuse of hearing aids (it must be clarified how the person feels about being in a group setting)\n   * Other physical or mental conditions with the above effect\n5. Conditions that may be the primary cause of fatigue:\n\n   * Long-term effects after COVID-19\n   * Chronic fatigue syndrome\n6. Participation in another research project that could affect fatigue (WORK-ON, INSELMA, SPINCODE)\n7. Participation in the fatigue program for hospitalized patients or support in another way specifically related to fatigue\n8. The participant must not have a planned rehabilitation stay (e.g., Danish Rheumatism Hospital, Sano, Montebello) or another program elsewhere that works with fatigue\n9. If the participant cannot commit to attending on the scheduled dates in one of the two programs.",{"count":75,"type":21},40,"INTERVENTIONAL",[78],"NA","Background: Inflammatory arthritis (IA) encompasses autoimmune rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Fatigue is highly prevalent in people with IA with 41-57% suffering from severe fatigue. Patients describe fatigue as overwhelming, unpredictable, challenging to manage, and affecting all areas of everyday life, including the ability to work. Studies have shown that interventions with physical activity or a cognitive behavioral approach can significantly reduce fatigue severity and\u002For impact in people with IA compared to usual care. To date, no studies have investigated the combined effect of CBA and PA on fatigue severity and impact in patients with IA. Therefore, the goal of this study is to test the feasibility of a newly developed fatigue intervention that combines a cognitive behavioral approach and physical activity (COMFI) in patients with inflammatory arthritis, who experience fatigue as a challenge in their everyday lives in Denmark and Sweden. The intervention will be tested in 4 groups (2 in Denmark and 2 in Sweden), and the participants will participate in 7 group sessions and 2 focusgroups interview in the evaluation.\n\nThe primary outcome for the participants is fatigue, measured through patient-reported outcomes at baseline, 3, 6, and 12 months after baseline.\n\nThis study will show if the intervention is feasible in practice and meaningful for the participants.",[81,82,30,83],"Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Inflammatory Arthritis",[85,86,87,88],"Fatigue","Intervention","cognitive behavioural approach","Physical activity","2025-08-14",{"date":91,"type":35},"2025-08-15",{"date":93,"type":35},"2024-10-01",{"date":95,"type":21},"2026-04",{"name":97,"class":42},"The Danish Center for Expertise in Rheumatology",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":108,"type":21},3500,"10 Years","Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[112,113,114,115,116,117,118,119,120,30,121],"Hereditary Autoinflammatory Diseases","Schnitzler Syndrome","Behcet Syndrome","PFAPA Syndrome","Still Disease","Autoinflammatory Syndrome, Unspecified","Uveitis","Scleritis","Vexas Syndrome","Castleman Disease","2025-07-07",{"date":124,"type":35},"2025-07-10",{"date":126,"type":35},"2020-08-06",{"date":128,"type":21},"2030-08-06",{"name":130,"class":42},"University of Siena",112,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":76,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100570434","phase-4-effect-and-safety-of-benzathine-penicillin-combined-with-etanercept-on-spondyloarthritis-100570434","NCT06707194","Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis","Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis: a Multicenter Randomized Controlled Clinical Study","Inclusion Criteria:\n\nThe following patients would be included: (1) The subjects voluntarily participate and sign an informed consent form; (2) patients aged 18-59 years; (3) According to the following guidelines or diagnostic criteria, a standardized diagnosis of spinal arthritis patients is made, which meets one of the following diagnostic criteria: ① 2009 ASAS classification criteria for axial spinal arthritis; ② Classification criteria for ASAS peripheral spondyloarthritis in 2011. And subjects with spinal arthritis who are in a relatively active period (ASDAS-CRP\\>1.2 )of infection;\n\nExclusion Criteria:\n\nhe exclusion criteria are as follows: (1) Subjects with nasopharyngitis, active tuberculosis, inflammatory bowel disease and other infections, other rheumatic and immune diseases, malignant tumors, and concomitant bone and joint diseases; (2) Individuals who are allergic to the components of the experimental drug; (3)Severe abnormalities in liver and kidney function (liver enzymes ≥ 2 times normal; creatinine ≥ 2 times normal); (4)Pregnant, preparing for pregnancy or breastfeeding women; (5)Moderate to severe heart failure (New York Heart Association grades 3-4); (6)Some researchers believe that other situations are not suitable for the use of etanercept or other experimental drugs; (7)Active gastrointestinal ulcer\u002Fbleeding; (8) According to the researcher's judgment, it is not suitable to participate in this study; (9)Patients in the acute phase of streptococcal infection: present with clinical manifestations of acute pharyngitis, acute tonsillitis, scarlet fever, and streptococcal pyoderma, and ASO or ADNS\\>normal range, and\u002For CRP\\>normal range.","59 Years",{"count":141,"type":21},340,[143],"PHASE4","The purpose of the study is to verify the clinical feasibility of Benzathine penicillin (BPG) \u002FEtanercept (ETN) combination regimen in patients with spondyloarthritis (SpA) and at the same time compare Benzathine penicillin \u002FEtanercept combination regimen and Etanercept maintenance therapy in reducing disease activity, improving patients' clinical symptoms and body function scores, enhancing quality of life, improving imaging performance and safety.",[30,146],"Ankylosing Spondylitis (AS)",[148,149,150],"spondyloarthritis","benzathine penicillin","Etanercept","2025-06-23",{"date":153,"type":35},"2025-06-26",{"date":155,"type":35},"2025-06-14",{"date":157,"type":21},"2027-07-31",{"name":159,"class":42},"Nanfang Hospital, Southern Medical University",6,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":139,"enrollmentInfo":168,"targetDuration":170,"studyType":22,"phases":4,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":43},"100592083","bidirectional-cohort-study-of-nanfang-spondyloarthritis-100592083","NCT06988813","Bidirectional Cohort Study of Nanfang Spondyloarthritis","BCNS","Inclusion Criteria:\n\n* 1.Attended Nanfang Hospital, Southern Medical University, 2010-2030 2.Prospective cohort study component: subjects voluntarily participate with informed consent and sign an informed consent form 3.Retrospective cohort study: (i) patients who visited the hospital from April 2010 to April 2024 (and who will not return to the hospital at a later date) were exempted from informed consent; (ii) patients who visited the hospital from May 2024 to April 2025 were required to sign an informed consent 4.10 years old ≤ age ≤ 59 years old 5.Patients with a standardized diagnosis of spondyloarthritis by the following guidelines or diagnostic criteria, i.e., meeting one of the following diagnostic criteria: (1) 2009 ASAS classification criteria for axial spondyloarthritis; (2) 2011 ASAS classification criteria for peripheral spondyloarthritis\n\nExclusion Criteria:\n\n* 1\\. Women who are pregnant, preparing for pregnancy or breastfeeding 2.Moderate to Severe Heart Failure (New York Heart Association Class 3-4) 3.Active peptic ulcers\u002Fbleeding 4.Judged by the investigator to be unsuitable for participation in this study",{"count":169,"type":21},3000,"4 Years","Spondyloarthritis（SpA） patients attending Nanfang Hospital of Southern Medical University will generate a large number of clinical condition scales, laboratory indicators, imaging data such as X-rays or MRIs in the course of multiple standardized follow-up visits, as well as medical specimens from some of the patients who undergo surgical treatments. The Department of Orthopaedic Surgery of Nanfang Hospital is looking forward to the future and proposes to establish a specialized cohort named \"Nanfang SpA Bidirectional Specialized Disease Cohort\" by simply recording the clinical and imaging data of the above patients who have attended the clinic, been treated routinely, and have been followed up in the department without any interventional research measures. The cohort is proposed to: (1) archive the disease characteristics, biochemical index data, and disease assessment scales of all SpA patients attending the Southern Hospital; (2) record the X-ray and magnetic resonance imaging data of the patients to establish the \"Southern SpA Imaging Dataset\". This provides strong support for subsequent SpA research projects and lays the foundation for subsequent large-scale transect studies and retrospective studies.",[30,146],[174],"Bidirectional Cohort","2025-05-16",{"date":177,"type":35},"2025-05-25",{"date":179,"type":21},"2025-05-17",{"date":181,"type":21},"2030-04-30",{"name":159,"class":42},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":76,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100575269","phase-4-vunakizumab-in-adults-with-spondyloarthritis-100575269","NCT06770088","Vunakizumab in Adults with Spondyloarthritis","A Prospective, Single-arm, Multicenter Study to Explore the Efficacy and Safety of Vunakizumab in Adults with Active Spondyloarthritis","V SPA","Inclusion Criteria:\n\n1. Patients older than 18 years when signing the informed consent;\n2. Patients diagnosed with spondyloarthritis (excluding psoriatic arthritis) and are eligible for biologic therapy;\n3. The subjects voluntarily signed informed consent before the start of any procedures related to the study, were able to communicate with the investigators smoothly, understood and were willing to strictly abide by the requirements of the clinical research protocol to complete the study.\n\nExclusion Criteria:\n\n1. Patients with severe hypersensitivity reaction to the active ingredient or any excipient of Vunakizumab;\n2. fertile women (defined as all women with the physical requirements for pregnancy) and men who are pregnant or who are unwilling or unable to use highly effective birth control during the study and within 20 weeks after last receiving the study drug;\n3. active infection with important clinical significance;\n4. patients with moderate to severe heart failure (NYHA class Ⅲ\u002FⅣ);\n5. patients with malignant tumors who were receiving treatment or were not receiving treatment;\n6. concomitant with other inflammatory diseases or severe autoimmune diseases, including but not limited to inflammatory bowel disease, which may affect the efficacy and safety evaluation according to the investigator's judgment;\n7. any other condition that the investigator considers would prevent the subject from adhering to and completing the study protocol.",{"count":192,"type":21},880,[143],"This prospective, single-arm, multicenter study is aimed to explore the efficacy and safety of Vunakizumab in adults with spondyloarthritis. The primary endpoint is the proportion of adults with spondyloarthritis achieving ankylosing spondylitis assessment score (ASAS) 40 at week 16 in the treatment of Vunakizumab.",[30],"NOT_YET_RECRUITING","2025-01-10",{"date":199,"type":35},"2025-01-13",{"date":197,"type":21},{"date":202,"type":21},"2027-12-31",{"name":204,"class":42},"Sun Yat-sen University"]